ARCA biopharma CEO Michael Bristow to Present in Two Sessions at the American Heart Associations Scientific Sessions 2015

Westminster, CO, November 5, 2015 – ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced that its President and CEO, Michael R. Bristow, M.D., Ph.D., will give two invited presentations at the American Heart Association Scientific Sessions 2015 ( held November 7-11, 2015 in Orlando, Florida.

The session “Emerging Pharmacological Approaches to Treat Heart Failure” will be held Sunday, November 8, 2015. Dr. Bristow will present “GPCR Polymorphisms driving heart failure therapeutic outcomes” at 8:00am ET.

The session “Phenotyping Heart Failure: Is this the Way Forward?” will be held Sunday, November 8, 2015. Dr. Bristow will present “Phenotyping Heart Failure Helpful New Tool?” at 9:00am ET.

ARCA is currently developing GencaroTM (bucindolol hydrochloride) as a potential treatment for atrial fibrillation in a genotype-defined heart failure population (heart failure patients with reduced left ventricular ejection fraction, HFREF). Earlier this year, the Gencaro development program was designated a Fast Track development program by the U.S. Food and Drug Administration. The Phase 2B/3 GENETIC-AF trial is currently recruiting patients at clinical trial sites in the
United States and Canada.

Atrial Fibrillation (AF)

Atrial fibrillation, the most common sustained cardiac arrhythmia, is considered an epidemic cardiovascular disease and a major public health burden. The estimated number of individuals with AF globally in 2010 was 33.5 million. According to the 2015 American Heart Association report on Heart Disease and Stroke Statistics, the estimated number of individuals with AF in the United States in 2010 ranged from 2.7 million to 6.1 million people. Hospitalization rates for AF
increased by 23% among U.S. adults from 2000 to 2010 and hospitalizations account for the majority of the economic cost burden associated with AF.

About ARCA biopharma

ARCA biopharma is dedicated to developing genetically-targeted therapies for cardiovascular diseases. The Company’s lead product candidate, GencaroTM  (bucindolol hydrochloride), is an investigational, pharmacologically unique beta-blocker and mild vasodilator being developed for atrial fibrillation. ARCA has identified common genetic variations that it believes predict individual patient response to Gencaro, giving it the potential to be the first genetically-targeted atrial fibrillation prevention treatment. ARCA has a collaboration with Medtronic, Inc. for support of the GENETIC-AF trial.  For more information please visit

Safe Harbor Statement

This press release contains “forward-looking statements” for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding, potential timeline for GENETIC-AF trial activities, the potential for genetic variations to predict individual patient response to Gencaro, Gencaro’s potential to treat atrial fibrillation, future treatment options for patients with atrial fibrillation, and the 
potential for Gencaro to be the first genetically-targeted atrial fibrillation prevention treatment. Such statements are based on management’s current expectations and involve risks and uncertainties.  Actual results and performance could differ materially from those  projected in the forward-looking statements as a result of many factors, including, without limitation, the risks and uncertainties associated with: the Company’s financial resources and whether they will be sufficient to meet the Company’s business objectives and operational requirements; results of earlier clinical trials may not be confirmed in future trials, the protection and market 
exclusivity provided by the Company’s intellectual property; risks related to the drug discovery and the regulatory approval process; and, the impact of competitive products and  technological changes. These and other factors are identified and described in more detail in ARCA’s filings with the SEC, including without limitation the Company’s annual report on Form 10-K for the year ended December 31, 2014, and subsequent filings. The Company disclaims any intent or obligation to update these forward-looking statements.

Investor & Media Contact:
Derek Cole 720.940.2163